Skip to main content

Table 5 QLQ-TC26 scores at the start of treatment, the end of treatment and post-treatment

From: International phase IV validation study of an EORTC quality of life questionnaire for testicular cancer patients: the EORTC QLQ-TC26

  On-Treatment Post-Treatment
T1on
N = 113
T2on
N = 49
  T1on vs T2ona T1post
N = 200
T2on vs T1posta
EORTC QLQ-TC26 Mean SD Mean SD Diff. F-statistic p-value Mean SD t-statistic p-value
Treatment Side Effects 12.3 15.1 17.1 15.2 4.8 10.841 0.002** 9.3 13.9 3.252 0.002**
Treatment Satisfaction 89.1 21.0 91.2 16.4 2.1 0.687 0.410 90.4 22.7 0.230 0.818
Future Perspective 61.9 27.4 65.3 23.0 3.4 0.339 0.563 66.9 26.9 −0.386 0.700
Family Problems 36.6 34.2 34.7 27.5 −1.9 0.481 0.491 22.8 29.7 2.537 0.012*
Infertility 36.6 37.3 27.9 31.4 −8.7 2.824 0.099 28.5 33.5 −0.115 0.908
Communication 81.7 26.1 83.7 23.9 2.0 1.022 0.316 82.3 24.1 0.350 0.727
Body Image Problems 13.6 23.8 23.6 33.7 10.0 6.124 0.016* 12.8 22.3 2.110 0.039*
Sexual Activity 54.9 29.0 40.5 31.4 −14.4 10.636 0.002** 63.7 27.2 −5.178 < 0.001**
Sexual Functioning 91.3 20.2 91.7 16.0 0.4 0.027 0.871 86.4 23.2 1.646 0.105
Job Education problems 32.4 35.8 16.3 24.6 −16.1 7.043 0.011* 12.5 26.6 0.915 0.361
Physical limitations 32.4 33.5 36.1 29.5 3.7 1.054 0.308 15.3 27.1 4.710 < 0.001**
Sexual Enjoyment 78.6 27.0 70.6 28.4 −8.0 5.410 0.025* 78.4 25.6 −1.613 0.108
Testicular Implant
Satisfaction
45.8 40.4 56.9 42.1 11.1 0.391 0.541 66.7 34.3 −0.973 0.334
  1. aT1on - first assessment time point in the on-treatment group before treatment start; T2on - second assessment time point in the on-treatment group at the end of treatment; T1post - first assessment time point in post-treatment group;
  2. *p< .05, **p< .01